cyrilzakka/clinical-trials huggingface dataset:
COMPARISON BETWEEN EFFICACY OF NOREPINEPHRINE AND PHENYLEPHRINE BOLUSES for PREVENTION OF SPINAL ANAESTHESIA INDUCED HYPOTENSION IN OBSTETRICAL PATIENTS UNDERGOING EMERGENCY CESAREAN SECTION-A Double Blind Randomized Controlled Trial

The goal of this clinical trial is to learn if norepinephrine is more effective than phenylephrine for prevention of spinal anesthesia induced hypotension. The main questions it aims to answer are:

Does norepinephrine lower the incidence of spinal anesthesia induced hypotension in emergency obstetrical patients? We will compare effectiveness of norepinephrine and phenylephrine for the prevention of spinal anesthesia induced hypotension.

Participants will:

Be administered prophylactic boluses of both drugs right after spinal anesthesia induction and maternal hemodynamic parameters and neonatal APGAR scores will be recorded

Spinal anesthesia is a common mode of anesthesia in cesarean delivery. Spinal anesthesia induced hypotension is one of the most common complication that can affect both mother and fetus. For the management of spinal anesthesia induced hypotension, preloading with crystalloids and colloids, use on ionotropic agents and vasopressors have already been in practice.

Objective of this study is to compare efficacy of prophylactic use of norepinephrine and phenylephrine bolus dosage for spinal anesthesia induced hypotension.

This study is being conducted at the department of anesthesiology ,K.M Pfau civil hospital, Dow university of health sciences, Karachi , Pakistan. Data is being collected after taking approval from Institutional review board and written informed consent from the participants.

Participants are being enrolled by primary investigator. All participants are undergoing simple randomization by lottery method.

After enrollment of participants, demographic data, hemodynamic parameters and other relevant details are being recorded till delivery of the neonate.

Hemodynamic parameters that are heart rate, systolic and diastolic blood pressure, mean arterial blood pressure is being recorded every 3mins. APGAR scoring of neonate is also being recorded.

After completion of data collection, data will be done using Statistical package for social sciences 26.

Eligibility Criteria:
Inclusion Criteria:

1. American society of anesthesiologists II and III patients
2. Age 18-40years
3. Gestational age 32 weeks and above

Exclusion Criteria:

1. Patients with hypertensive disorders of pregnancy having baseline systolic blood pressure greater than 160 mmHg and diastolic blood pressure greater than 99 mmHg.
2. Baseline mean arterial pressure less than 70 mmHg.
3. Antepartum hemorrhage/intraoperative blood loss greater than 1000ml
4. history indicative of cardiovascular or neurological disease.
5. known fetal abnormality.
6. Patients taking serotonin reuptake inhibitor, Tricyclic antidepressants,monoamine oxidase inhibitors.
7. Maternal situations requiring immediate administration of general anesthesia
Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19

The SARS-CoV-2 infection in the airway epithelium induces cytopathic effects and the cessation of ciliary movement. Increased cytokines and chemokines have been reported to be associated with the severity of the disease. However, most of the molecular and cellular aspects of the inflammatory response and the processes of development of humoral and cellular immunity in these patients are unknown. The aim of this study is characterizing inflammatory processes, seeking to expand the knowledge of the cellular and molecular pathophysiology of COVID-19 that could help in the decision-making of treating health personnel. Mainly, the study is focused on analyzing the inflammatory response by determining cytokines and chemokines. Also, the viral load of the patients with COVID-19 will be determined and will be correlated with the antibody titers. On the other hand, cells will be immunophenotyped to search the cellular depletion profile. Finally, an epidemiological analysis of the patients will be carried out.


Eligibility Criteria:
Inclusion Criteria:

* Patients over 16 years old with positive molecular diagnosis of Covid-19, in the Laboratory of IMSS

Exclusion Criteria:

* Patients with immunosuppressive diseases: HIV +, Hepatitis C virus, primary immunodeficiencies, rheumatoid arthritis, lupus erythematosus and patients under treatment with immunosuppressants
Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)

To investigate the pharmacodynamics and safety of FYU-981 administered orally once a day for 14 weeks, to uric acid-overproduction type or uric acid-underexcretion type of male hyperuricemic outpatients with or without gout.


Eligibility Criteria:
Inclusion Criteria:

* Serum urate level:

  * \>= 7.0mg/dL in patients with gouty nodule or with history of gout, or \>=8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL
* Disease type in the classification of hyperuricemia: Uric acid-overproduction type or Uric acid-underexcretion type
* Outpatients

Exclusion Criteria:

* Gouty arthritis within 14 days before randomized allocation
A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis

Pleurodesis is a technique used to fuse the two layers of the lining over the lung. This is done to get rid of collections of fluid or air in this space. A common reason would be cancer of the underlying lung or elsewhere causing fluid to collect in the pleural space. In this situation it is a palliative procedure to free the patient from symptoms like breathlessness.

Pleurodesis is a technique used to fuse the two layers of the pleura. This is done to prevent reaccumulation of collections of fluid or air in this space. Common indications are malignant pleural effusions, recurrent pneumothorax and even benign effusions which are otherwise difficult to eradicate.

Eligibility Criteria:
Inclusion Criteria:

* Age over 12 years
* Symptomatic recurrent pleural effusion
* Pneumothorax needing pleurodesis

Exclusion Criteria:

* Life expectancy \<1 month
* Unwilling to give consent
* Empyema
* ICTD drain output \>150 ml/d
* Presence of an airleak
Celecoxib as a Post-tonsillectomy Pain Medication

The hypothesis is that celecoxib effectively reduces pain after a tonsillectomy and reduces post-operative narcotic use.

To test this hypothesis, the study is placebo controlled (sugar pill). Half of the participants will receive a sugar pill, half will not.

All participants will receive the standard post-operative pain medications.

We ask participants to log the amount of medications they use daily, and the amount of pain they have each day. It is hoped that celecoxib will reduce the amount of post-operative pain medication needed.

Post-tonsillectomy pain is typically controlled through narcotic medications, such as Lortab elixir. Despite its standard use, this pain control is typically not as effective as a non-steroidal anti-inflammatory medication (NSAID). The problem with using NSAIDs for post-tonsillectomy operative pain is the significant increased risk of rebleeding.

Celecoxib is an NSAID that is a COX-2 inhibitor; the drug is designed to act as an NSAID without the increased risk of rebleeding or hemorrhage.

This study is a double blind, randomized study; neither the study participant or the study investigator knows if the participant is receiving celecoxib or a placebo (sugar pill). The blinded list is maintained by the research pharmacists and can be unblinded when needed (such as in an emergency).

Participants begin taking the study medication the night before surgery and continue through 10 days post-operative. Participants are asked to complete a journal that catalogs the amount of standard post-operative medications taken, the amount of pain experienced, and any other comments.

Participants are contacted by phone at 5 and 10 days post-op.

Study participation ends at the standard 3-week post-operative check-up.

Eligibility Criteria:
Inclusion Criteria:

* Age at least 18 years
* Indication for tonsillectomy (patients undergoing a tonsillectomy as a portion of additional surgical procedures will not be included)
* Have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* History of bleeding disorders
* History of liver or kidney dysfunction
* History of allergy to sulfa containing medications
* History of lactose intolerance
* History of asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs
* Women who are currently pregnant, nursing, or trying to conceive
* History of allergy or intolerance to acetaminophen or hydrocodone
* History of allergy to any COX-2 inhibitor, including celecoxib or rofecoxib.
* PT, PTT, hemoglobin, or hematocrit values that are outside of institutional limits.
* History of cardiovascular disease
* Patients currently taking celecoxib
Longitudinal Study of Frailty in Shanghai Older People

To investigate the prevalence of Frailty in community older residents.

Detailed Description:

1. Objective:

   * To investigate the prevalence of Frailty in community older residents.
   * To explore the causes and risk factors of frailty.
2. Method:

   * The survey is a Community-based, multicenter prospective cohort study.

     1). 6,000 participants are expected to be included.
   * Through a questionnaire and physical examination form, carries on the investigation to the more than 65 years old people during the 3-year follow-up period.
   * The questionnaires include survey date, participant characteristics and related risk factors, such as comprise demographic characteristics, Chinese ethnic nationality, marital status, education level, family incomes, occupation, pregnancy and parity history, menstrual history, frequency and amount of daily smoking and alcohol drinking, frequency of urination and defecation, dietary habits, hours per day of sleep and sun exposure. Medical history including medication use and disease status for comorbidities, will be obtained from participants' medical records. Syndrome differentiation of deficiency of the five zang-organs in TCM will be analyzed.
   * Height and body weight will be measured for body mass index (BMI) calculation. The waist circumference and hip circumference will be recorded, and the ratios calculated. The muscle strengths of both hands will be measured with a hand dynamometer. Each of these measures will be assessed twice and the average score used in analyses.
   * Subjects will be asked to walk a distance of 4 meters and record the time at the same time to measure the walking speed.
   * Clock Drawing Test (CDT), physical frailty examination, Mini-Mental State Examination (MMSE), Skeletal muscle mass index (SMI) will also be conducted or calculated .
   * Each participant will provide a total of 7 mL of venous blood after an overnight fast (10-hour).

After being collected, markers of frailty will be measured, such as Interleukin-6 (IL-6), insulin-like growth factor-1 (IGF-1) and estrogen (E). And blood routine, urine routine, liver and kidney function, fasting plasma glucose, serum lipid will be detected.

* Physicians in each community as the backbone, Shanghai Geriatric Institute of Chinese Medicine is responsible for personnel training.
* Shanghai community health service centers are responsible for organization and coordination.

Eligibility Criteria:
Inclusion Criteria:

* more than 65 years old
* Permanent residence in Shanghai and long-term residence in the community implemented by this project (more than five years)
* Be willing to and be able to join in the study and signed Informed consent.

Exclusion Criteria:

* Excluding the patients whose physical function is affected by diseases or disabilities such as stroke, Parkinson's disease, tumor, fracture, etc.
* Excluding schizophrenia, depression, anxiety and other mental diseases and dependent on drug control.
* If they were unable to complete the study survey.
* Unwilling to join in the study and don't sign Informed consent.
Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides

The purpose of this study is to determine the effects of supplementing diets of hyperlipidemic men with DHA (docosahexenoic acid) on risk factors for cardiovascular disease. We hypothesize that supplementing diets of hyperlipidemic men with DHA will decrease the plasma concentrations of CRP (C-reactive protein), inflammatory cytokines, and soluble adhesion molecules. We further hypothesize that DHA supplementation will decrease serum triglyceride concentrations and increase HDL concentration.

Cardiovascular disease (CVD) and stroke are the leading causes of mortality in the United States, accounting for more than 38% of all deaths. Elevated total- and LDL- cholesterol, number of total and small dense LDL particles, triacylglycerols, and low HDL-C are established independent risk factors for the development of CVD. Additional novel blood lipid markers used as risk factors for CVD include, increased plasma concentration of remnant like particle-cholesterol (RLP-C), decreased ratio between plasma eicosapentaenoic acid (EPA) and arachidonic acd (AA), and decreased omega-3 index (sum of EPA and DHA as a percentage of total fatty acid content) of the red blood cells.

Diets rich in omega-3 fatty acids have been shown to be cardio-protective; these diets decreased inflammation, platelet aggregation, cardiac arrhythmias, triglycerides, number of total LDL and small dense LDL particles, and increased omega-3 index, endothelial relaxation and atherosclerotic plaque stability. Most of the earlier studies regarding the effects of long chain n-3 PUFA on blood lipids were conducted with fish oils which contain a mixture of EPA and DHA. Recently a number of studies have been conducted with EPA and DHA individually. Results from studies with individual fatty acids show that EPA and DHA have similar effects on some of the lipid parameters, but they are assimilated to a different concentration in tissues and have different effects on lipoprotein particle size, heart rate and blood pressure. The main purpose of this study is to examine the effects of DHA supplementation on the above three risk factors.

Eligibility Criteria:
Inclusion Criteria:

* fasting serum triglyceride values of 150-400 mg/dL
* total cholesterol \< 300 mg/dL
* LDL-cholesterol \< 220 mg/dL
* BMI between 22 and 35 Kg/m2

Exclusion Criteria:

* anti-inflammatory medications including steroids
* antihypertensives
* non sulfonyl urea medications for diabetes mellitus
* drugs that alter serum triacylglycerols and HDL-C levels (i.e. fibrates)
* niacin supplements
* consumers of illegal substances
* consumers of more than 5 drinks of alcohol per week
* more than one fish meal per week
* dietary supplements of fish oil, flaxseed oil or vitamin C or E
Validity and Reliability of a Turkish Version of MD Anderson Inventory Dysphagia Inventory

The purpose of this study is to M.D. Validity of the Turkish version of the Anderson Dysphagia Inventory for the Turkish population, reliability, and cultural adaptation.

Oropharyngeal dysphagia (OD) is a common finding in patients with neurogenic disorders.

Swallowing disorder can be acute or chronic in nature. For example, acute OD is observed in patients after stroke, head trauma, neurosurgical intervention, or in patients with Guillain-Barré syndrome. Chronic OD may develop in patients who do not recover after a stroke. Degenerative OD, Parkinson's disease, amyotrophic lateral sclerosis, myasthenia gravis, Huntington's disease, myotonic dystrophy type 1 and multiple sclerosis It is seen in patients with progressive neurological diseases. The prevalence of OD in neurogenic patients varies from 3% to 50% in stroke patients and up to almost 100% in patients with Huntington's disease. The OD can lead to weight loss, malnutrition, social isolation, aspiration pneumonia, and reduced health-related quality of life (QoL). Some studies have reported that dysphagia-specific QoL is weakly associated with OD severity measured using, among other things, fiberoptic endoscopic evaluation of swallowing (FEES) and videofluoroscopy of swallowing (VFS). Therefore, dysphagia-specific QoL questionnaires used alongside these instrumental assessments add value by providing insight into patients' perception of OD, which can be taken into account in the treatment plan. There are dysphagia-specific quality-of-life questionnaires that are actively used today: Swallowing Quality of Life Questionnaire (SWAL-QOL, 44 items), Swallowing Disability Index (30 items), Dysphagia Handicap Index (25 items) and M.D. Anderson Dysphagia Inventory (MDADI, 20 items). Multidisciplinary dysphagia clinics in our country mostly focus on the head and neck. It is visited by patients with OD of oncological or neurological origin.The M. D. Anderson dysphagia inventory is an easier inventory to perform since it has a smaller number of questions and contains more standard questions compared to other currently used questionnaires. Other questionnaires, such as the SWAL-QOL-TR and the Swallowing Disability Index, are longer than the MDADI and take more time to complete. The purpose of this study is M.D. Validity of the Turkish version of the Anderson Dysphagia Inventory for the Turkish population, reliability and cultural adaptation.

Eligibility Criteria:
Inclusion Criteria:

Group 1:

* Diagnosed with neurologic disorder
* Able to speak, read, understand and write in Turkish
* History of dysphagia during 6 months

Group 2:

* Able to speak, read, understand and write in Turkish
* Healthy adults

Exclusion Criteria:

* Mini Mental State Examination score below 23 points
* History of head and neck cancer (HNC),
* Age below 18 or above 85 years.
Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene

This protocol serves as a data collection tool for individuals with variants (missense, nonsense, frameshifts) in the IRF2BPL gene (MIM 611720), which causes Neurodevelopmental Regression, Seizures, Autism and Developmental Delay (NEDAMSS, MIM 618088) and may be involved in other neurodevelopmental presentations. This information will be analyzed to develop a better understanding of the findings and progression of symptoms in individuals with variants in the IRF2BPL gene.

Neurodevelopmental Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS) is caused by changes in the IRF2BPL gene. Variants in the gene can also lead to other neurodevelopmental presentations. Due to the limited number of cases that have been described to date, clinicians may have a limited understanding of what types of symptoms can develop in affected individuals and at what age. The purpose of the study is to gather clinical information about progression, treatments and outcomes for patients with variants in IRF2BPL. The investigators will collect information about medical history, growth, development, treatments and the results of previous genetic tests. In some cases, the investigators may also collect tissue samples. This is a non-interventional study that will expand the current understanding of the range of health concerns that can be seen in individuals with changes in the IRF2BPL gene by collecting medical information and samples from a larger group of affected individuals.

Eligibility Criteria:
Inclusion Criteria:

* Living or deceased individuals with variants in the IRF2BPL gene

Exclusion Criteria:

* None
Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.

This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 36 subjects with moderate to severe Chronic Spontaneous Urticaria.

Successfully screened subjects will be randomized in a ratio of 1：1：1. After a 4-week screening period (day -28-0), subjects will be randomly assigned to treatment for 12 weeks.

Clinical Urticaria Activity Score (UAS), dermatological Quality of Life Index (DLQI), physical exams and Laboratory tests will be performed at baseline, the end of weeks 4, 8 and 12 respectively.

Eligibility Criteria:
Inclusion Criteria:

* Have had a diagnosis of moderate to severe Chronic Spontaneous Urticaria for at least 6 months prior to Baseline;
* Subjects with moderate to severe Chronic Spontaneous Urticaria UAS7 score ≥16 at Baseline;
* Able and willing to give written informed consent.

Exclusion Criteria:

* Other types of Chronic Urticaria (such as Artificial urticaria, cold-contact urticaria, heat-contact urticaria etc);
* Other disease with symptoms of urticaria or angioedema, e.g., Urticaria vasculitis, color Vegetarian urticaria, erythema multiforme;
* History or symptoms of malignancy in any organ system regardless of treatment, and regardless of evidence of recurrence or metastasis;
* Any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the subject's participation in the study.
Tegoprazan and Amoxicillin Dual Therapy

Dual therapy for Helicobacter pylori refers to a treatment regimen that combines two agents: a potent acid suppressor (such as a proton pump inhibitor \[PPI\] or a potassium-competitive acid blocker \[PCAB\]) and the antibiotic amoxicillin. This approach is increasingly recognized as a viable alternative to traditional triple or quadruple therapies, particularly in the context of rising resistance to other antibiotics such as clarithromycin and metronidazole. Potent acid suppression increases the stability and activity of amoxicillin against H. pylori by maintaining a higher gastric pH, which is essential for optimal amoxicillin effect. High-dose dual therapy (e.g., amoxicillin 1,000 mg three times daily + standard dose of PPI three or four times daily for 14 days) has demonstrated eradication rates of 90%. In 2015, vonoprazan, a novel P-CAB, was launched in Japan and used as an alternative for PPIs for eradicating H. pylori. Dual therapy with vonoprazan and amoxicillin is particularly effective, with cure rates comparable to triple therapy and superior outcomes in clarithromycin-resistant infections. Dual therapy is generally well tolerated, with adverse event rates similar to or lower than those seen with triple or quadruple regimens. In 2018, a new P-CAB, tegoprazan, was developed in Korea and approved for H. pylori eradication. However, there was no study of tegoprazan and amoxicillin dual therapy for the treatment of H. pylori.

The investigators aim to evaluate the H. pylori eradication success rate and treatment compliance of tegoprazan and amoxicillin dual therapy.

Eligibility Criteria:
Inclusion Criteria:

* Gastroscopy can be performed
* H. pylori test and pathological analysis can be performed

Exclusion Criteria:

* Age \< 20 or \> 80 years
* Anemia (serum hemoglobin level \< 10 g/dL)
* Severe systemic disease
* Advanced chronic liver disease
* Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics
* History of H. pylori eradication
* Drug allergy to antibiotics
* History of gastric surgery
* Recent history of upper gastrointestinal bleeding